The Effect of Rosuvastatin in Diabetic Polyneuropathy: A Phase IIa Randomized Double-blind Placebo-controlled Study

Phase IIa Randomized Double-blind Placebo-controlled Study to Evaluate the Effect of Rosuvastatin in Diabetic Polyneuropathy

To evaluate the impact of oral rosuvastatin in diabetic polyneuropathy, and the role of lipid peroxidation and nerve growth factor.

Inclusion Criteria:

• Patients with type 2 diabetes mellitus
• Glycated hemoglobin <12.0%
• Signing of informed consent
• Presence of an abnormality of nerve conduction study
• Symptoms and signs of diabetic polyneuropathy

Exclusion Criteria:

• Pregnancy and lactation
• Foot ulcers
• Treatment with statins
• Antioxidant drug and/or supplements one month previous to enrolment
• Inability to mobilize
• Renal and/or hepatic failure